EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression

Guoli Yao, Yang Yang, Chunmei Chen, Bingrong Zheng, Tao Qiu, Lin Yang, Meiwei Hu

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.112204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Guoli Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, First People's Hospital of Linping District, Hangzhou, China. Hauptthemen laut MEDLINE: Kinesins, Leukemia, Myeloid, Acute, RNA-Binding Proteins, Ubiquitin-Protein Ligases. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a challenging hematological malignancy characterized by poor clinical outcomes. This study investigates the role of MYCBP2 in AML progression, focusing on its interaction with KIF14 and its involvement in ubiquitin-mediated processes. We found that MYCBP2 is overexpressed in AML samples compared to normal tissues, with high expression correlating with adverse clinical outcomes. Knockdown of MYCBP2 using siRNA significantly inhibited cell proliferation and promoted apoptosis in MOLM-13 and HL-60 AML cell lines. Flow cytometry revealed that MYCBP2 knockdown leads to cell cycle arrest in the G0/G1 phase. Gene Set Enrichment Analysis indicated that MYCBP2 is associated with the Ubiquitin-Mediated Proteolysis pathway, regulating KIF14 protein stability through ubiquitination. High KIF14 expression was linked to better overall survival, and KIF14 knockdown partially reversed the effects of MYCBP2 knockdown on cell viability and apoptosis. In vivo studies demonstrated that MYCBP2 knockdown significantly reduced tumor growth and enhanced apoptosis in a xenograft model. These findings support that MYCBP2 promotes AML progression at least in part by negatively regulating KIF14 stability, highlighting MYCBP2 as a potential therapeutic target. Future research should explore targeted therapies aimed at MYCBP2 and its downstream pathways to improve treatment strategies for AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KinesinsLeukemia, Myeloid, AcuteRNA-Binding ProteinsUbiquitin-Protein LigasesHumansAnimalsApoptosisCell ProliferationDisease ProgressionMiceCell Line, TumorOncogene ProteinsAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

AMLKIF14MYCBP2ubiquitin-proteasome system

Substanzen

KinesinsKIF14 protein, humanMYCBP2 protein, humanRNA-Binding ProteinsUbiquitin-Protein LigasesOncogene ProteinsAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Department of Hematology, First People's Hospital of Linping District, Hangzhou, China.
  • Department of Hematology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of Hematology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: humeiwei@sina.cn.

Zitieren

APA

Yao, G., Yang, Y., Chen, C., Zheng, B., Qiu, T., Yang, L., & Hu, M. (2026). Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.112204

Vancouver

Yao G, Yang Y, Chen C, Zheng B, Qiu T, Yang L, et al. Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.112204

BibTeX
@article{Yao2026,
  author = {Yao, Guoli and Yang, Yang and Chen, Chunmei and Zheng, Bingrong and Qiu, Tao and Yang, Lin and Hu, Meiwei},
  title = {Ubiquitin E3 ligase MYCBP2 targets KIF14 and contributes to acute myeloid leukemia progression},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.112204}
}
Kostenlos starten →